The Chanhassen-based company plans to use the funds on a randomized trial of its “sonodynamic therapy” for glioblastoma.

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical, Inc. (NYSE: GMED) announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the company’s common stock.

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

Globus Medical’s board of directors authorized a share repurchase program of up to $500 million of the company’s outstanding common stock. Timing and number of repurchased shares will be determined by ...

Investors are betting millions on a novel drug-device treatment from Chanhassen-based Alpheus Medical Inc. that uses ...

What Happened? A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5% ...

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after market close. Here’s what to look for. Globus Medical beat analysts’ revenue expectations ...

NEW YORK (May 6, 2025) — Bulletproof Your Marketplace: Strategies for Protecting Your Digital Platform by Jeremy H. Gottschalk is available today on Amazon. The book is published with Forbes ...

“We learned what the good balance is between scientific data and marketing information.” From there, the founders joined the UVA LVG I-Corps program, funded by the National Science Foundation and run ...

May 5 (Reuters) - KKR (KKR.N), opens new tab co-founder George Roberts tried to ease investor anxiety on Monday as uncertainty over U.S. President Donald Trump's trade policies have caused global ...